NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
June 5, 2025
Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the complex cycle of weight regulation Oral, brain-penetrant NLRP3 inflammasome inhibitor being investigated